Coherus Oncology, Inc.
For the period ended Dec 31, 2025. Filed Mar 9, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 9, 2026
CHRS$0.82+6.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| | | | | | | |
|---|---|---|---|---|---|---|
| · · December 31, | ||||||
| · · 2025 · · 2024 | ||||||
| Assets · · · · · | ||||||
| Current assets: · · · · · | ||||||
| Cash and cash equivalents | | $88,879 | | $125,987 | ||
| Investments in marketable securities | | | 83,246 | | | — |
| Trade receivables, net | | 17,815 | | 111,324 | ||
| TSA receivables, net | | | 603 | | | 11,010 |
| Inventory | | 3,172 | | 4,207 | ||
| Prepaid manufacturing | | 6,758 | | 6,653 | ||
| Other prepaids and current assets | | | 6,233 | | 10,222 | |
| Assets of discontinued operations, current (Note 6) | | — | | | 72,180 | |
| Total current assets | | 206,706 | | 341,583 | ||
| Property and equipment, net | | 1,345 | | 2,576 | ||
| Intangible assets, net | | 46,239 | | 53,646 | ||
| Other assets, non-current | | | 4,053 | | 6,485 | |
| Assets of discontinued operations, non-current (Note 6) | | — | | | 44,243 | |
| Total assets | | $258,343 | | $448,533 | ||
| | | | | | | |
| Liabilities and Stockholders’ Equity (Deficit) | | | | | ||
| Current liabilities: | | | | | ||
| Accounts payable | | $9,915 | | $28,456 | ||
| Accrued rebates, fees and reserves | | 30,397 | | 164,867 | ||
| TSA payables and accrued liabilities | | | 65,065 | | | 11,026 |
| Accrued compensation | | 14,579 | | 18,344 | ||
| Accrued and other current liabilities | | 20,430 | | 60,288 | ||
| Total current liabilities | | 140,386 | | 282,981 | ||
| Term loan, non-current | | | 37,051 | | | 36,698 |
| Convertible notes, non-current | | | — | | | 228,229 |
| Lease liabilities, non-current | | 1,457 | | 3,286 | ||
| Other liabilities, non-current | | 18,435 | | 29,329 | ||
| Total liabilities | | 197,329 | | 580,523 | ||
| Commitments and contingencies (Note 9) | | | | | ||
| Stockholders’ equity (deficit): | | | | | ||
| Preferred stock ($0.0001 par value; shares authorized: 5,000,000; shares issued and outstanding: 0 at December 31, 2025 and December 31, 2024) | | | — | | | — |
| Common stock ($0.0001 par value; shares authorized: 300,000,000; shares issued and outstanding: 121,154,925 and 115,614,548 at December 31, 2025 and December 31, 2024, respectively) | | 12 | | 12 | ||
| Additional paid-in capital | | 1,444,166 | | 1,419,266 | ||
| Accumulated other comprehensive loss | | (195) | | (275) | ||
| Accumulated deficit | | (1,382,969) | | (1,550,993) | ||
| Total stockholders' equity (deficit) | | 61,014 | | (131,990) | ||
| Total liabilities and stockholders’ equity (deficit) | | $258,343 | | $448,533 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.